Pfizer lays out ambitious vision for cancer portfolio in bid to reinvigorate its business

Pfizer hopes that its current pipeline could deliver at least eight cancer blockbuster drugs by 2030 as part of its strategy to double down on its oncology business after the Seagen acquisition.

In December, the pharma giant closed the $43 billion acquisition of the antibody-drug conjugate developer and has since…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks